J. Goldman & Co’s OnKure Therapeutics OKUR Stock Holding History

J. Goldman & Co’s Portfolio OKUR Stock Details OKUR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-6,750	Closed	-$108K	–	544
2023 Q4	$108K	Buy	+6,750	New	+$421K	﹤0.01%	309

Other funds holding OKUR

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

J. Goldman & Co's OKUR Position: Q4 2023 in Review

J. Goldman & Co sold out of OnKure Therapeutics (OKUR) in Q4 2023, closing a stake of 15,541 shares — an estimated $968K sold.

J. Goldman & Co first reported a position in OKUR in Q2 2023 and held it in 2 quarters. The position peaked at $2.01M in Q2 2023. 68 funds tracked by Wall St. Rank hold OKUR as of Q4 2023.

J. Goldman & Co reported no remaining OnKure Therapeutics position as of Q4 2023 after selling out during the quarter.
J. Goldman & Co sold 15,541 OnKure Therapeutics shares in Q4 2023, an estimated $968K.
J. Goldman & Co first reported a position in OnKure Therapeutics in Q2 2023 and held it in 2 quarters.
J. Goldman & Co's OnKure Therapeutics position peaked at $2.01M in Q2 2023.
68 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q4 2023.

Based on J. Goldman & Co's 13F filing for Q4 2023, filed 14 Feb 2024.